Lupinacci, R. Et Al. 2022. 336 A phase 3, multicenter, randomised, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of v114 in healthy infants (PNEU-PED). Royal College of Paediatrics and Child Health, Abstracts of the RCPCH Conference, Liverpool, 28–30 June 2022 , (Liverpool, England), 204.

Lupinacci, R., Rupp, R., Wittawatmongkol, O., Jones, J., Quiñones, J., Ulukol, B., ... Dagan, R.(2022). 336 A phase 3, multicenter, randomised, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of v114 in healthy infants (PNEU-PED) . Royal College of Paediatrics and Child Health, Abstracts of the RCPCH Conference, Liverpool, 28–30 June 2022 (pp.204). Liverpool, England

Lupinacci, Robert Et Al. "336 A phase 3, multicenter, randomised, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of v114 in healthy infants (PNEU-PED)," Royal College of Paediatrics and Child Health, Abstracts of the RCPCH Conference, Liverpool, 28–30 June 2022, Liverpool, England, 2022

Lupinacci, Robert Et Al. "336 A phase 3, multicenter, randomised, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of v114 in healthy infants (PNEU-PED)." Royal College of Paediatrics and Child Health, Abstracts of the RCPCH Conference, Liverpool, 28–30 June 2022 , Liverpool, England, pp.204, 2022

Lupinacci, R. Et Al. (2022) . "336 A phase 3, multicenter, randomised, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of v114 in healthy infants (PNEU-PED)." Royal College of Paediatrics and Child Health, Abstracts of the RCPCH Conference, Liverpool, 28–30 June 2022 , Liverpool, England, p.204.

@conferencepaper{conferencepaper, author={Robert Lupinacci Et Al. }, title={336 A phase 3, multicenter, randomised, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of v114 in healthy infants (PNEU-PED)}, congress name={Royal College of Paediatrics and Child Health, Abstracts of the RCPCH Conference, Liverpool, 28–30 June 2022}, city={Liverpool}, country={England}, year={2022}, pages={204} }